Receptor Binding, Affinity, and Specificity

Receptor binding is the molecular handshake that begins drug action: a drug must recognise and attach to a defined site on its target. Two properties govern how useful that recognition is — affinity, which measures how tightly the drug holds on, and specificity, which measures how well it discriminates its intended target from everything else.

Definition

Affinity is the strength of the reversible association between a drug and its binding site, conventionally expressed as the equilibrium dissociation constant (Kd, the concentration at which half the sites are occupied); specificity (selectivity) is the degree to which a drug binds its intended target in preference to other sites.

Scope

This topic covers the forces that hold a drug at its binding site, the quantitative description of affinity through the equilibrium dissociation constant, and the structural complementarity that gives a drug its selectivity for one receptor over others. It treats binding as a reference concept in pharmacodynamics and excludes any dosing or prescribing guidance.

Core questions

• What molecular forces hold a drug at its receptor site?
• How is affinity quantified, and what does the equilibrium dissociation constant mean?
• Why do some drugs bind one receptor subtype but not closely related ones?
• How does structural complementarity between drug and site determine selectivity?

Key concepts

• Equilibrium dissociation constant (Kd)
• Non-covalent binding forces (ionic, hydrogen bond, van der Waals, hydrophobic)
• Covalent and irreversible binding
• Selectivity versus specificity
• Structure-activity relationship
• Receptor subtype discrimination
• Lock-and-key and induced-fit complementarity

Key theories

Affinity-efficacy distinction

The principle that the strength of binding (affinity) is conceptually and quantitatively separate from the ability of the bound drug to produce an effect (efficacy), so that a high-affinity ligand may be an agonist, partial agonist, or antagonist.

Mechanisms

A drug associates with its binding site mainly through reversible non-covalent forces — ionic attractions, hydrogen bonds, van der Waals contacts, and the hydrophobic effect — whose summed strength defines the affinity of the interaction; covalent bond formation, when it occurs, produces a much longer-lasting and often effectively irreversible complex. Affinity is captured by the equilibrium dissociation constant Kd, the free-drug concentration at which half of the available sites are occupied, so that a lower Kd denotes higher affinity. Specificity arises from the three-dimensional complementarity between the drug and the contours and chemistry of the site: the closer the geometric and electrostatic match, the more the drug favours that site over related ones, which is the basis for selectivity among receptor subtypes. Because binding and the downstream response are distinct steps, the same affinity can accompany very different functional outcomes.

Clinical relevance

Affinity and selectivity are the properties most often used to compare drugs that act at the same family of receptors and to reason about why one agent engages a narrower set of targets than another. They describe the molecular basis of drug action at a reference level and do not constitute advice on choosing or dosing a medicine.

Evidence & guidelines

The quantitative conventions for affinity (Kd, and related parameters derived from binding assays) and the consensus terminology for receptors and their ligands are maintained by the International Union of Basic and Clinical Pharmacology (IUPHAR) and set out in standard pharmacology references.

History

The notion that a drug must fit a specific receptive site descends from Ehrlich's dictum that a substance acts only if it binds, and from Langley's and Clark's early formalisation of receptor occupancy by mass action. Stephenson's 1956 separation of affinity from efficacy clarified that tight binding does not by itself imply a large effect, and Colquhoun's later mechanistic analyses sharpened how affinity and specificity should be interpreted from structure-activity and mutagenesis data.

Key figures

• Paul Ehrlich
• Alfred J. Clark
• R. P. Stephenson
• David Colquhoun

Seminal works

• stephenson-1956
• colquhoun-1998

Frequently asked questions

Does higher affinity always mean a stronger drug effect?

No. Affinity describes how tightly a drug binds, not how much effect it produces; an antagonist can bind with very high affinity yet produce no activating effect at all.

What makes a drug selective for one receptor?

Selectivity comes from how closely the drug's shape and chemistry match a particular binding site; the better the complementarity to one site relative to others, the more the drug favours that target.